Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT03027674

Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud

Color Doppler Ultrasound Comparison of Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud: A Randomized, Double-blind, Placebo-controlled Pilot Study

Sponsor: Pontificia Universidad Catolica de Chile

Conditions Dermatomyositis Lupus Erythematosus, Systemic Raynaud Disease Raynaud Phenomenon Due to Trauma System; Sclerosis Ultrasound Therapy; Complications

Interventions 10% nifedipine cream 5% sildenafil cream

Updated 5 times since 2017 Last updated: Jan 19, 2017 Started: Aug 31, 2016 Primary completion: Aug 31, 2016 Completion: Aug 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03027674, this EARLY_PHASE1 trial focuses on Dermatomyositis and Lupus Erythematosus, Systemic and remains completed. Sponsored by Pontificia Universidad Catolica de Chile, it has been updated 5 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed EARLY_PHASE1

First recorded

Aug 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pontificia Universidad Catolica de Chile

Data source: Pontificia Universidad Catolica de Chile

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Santiago, Chile